<SEC-DOCUMENT>0001193125-13-142097.txt : 20130404
<SEC-HEADER>0001193125-13-142097.hdr.sgml : 20130404
<ACCEPTANCE-DATETIME>20130404160513
ACCESSION NUMBER:		0001193125-13-142097
CONFORMED SUBMISSION TYPE:	8-K/A
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20130329
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20130404
DATE AS OF CHANGE:		20130404

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DYNAVAX TECHNOLOGIES CORP
		CENTRAL INDEX KEY:			0001029142
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				330728374
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34207
		FILM NUMBER:		13743240

	BUSINESS ADDRESS:	
		STREET 1:		2929 SEVENTH STREET
		STREET 2:		SUITE 100
		CITY:			BERKELEY
		STATE:			CA
		ZIP:			94710
		BUSINESS PHONE:		5108485100

	MAIL ADDRESS:	
		STREET 1:		2929 SEVENTH STREET
		STREET 2:		SUITE 100
		CITY:			BERKELEY
		STATE:			CA
		ZIP:			94710
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K/A
<SEQUENCE>1
<FILENAME>d516621d8ka.htm
<DESCRIPTION>8-K/A
<TEXT>
<HTML><HEAD>
<TITLE>8-K/A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Washington, D.C. 20549 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>Form 8-K/A
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>(Amendment No.&nbsp;1) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>Current
Report </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Pursuant to Section&nbsp;13 or 15(d) of </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>the Securities Exchange Act of 1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Date of Report (Date of earliest event reported):&nbsp;March 29, 2013 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>Dynavax
Technologies Corporation </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact name of registrant as specified in its charter) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Commission File Number:&nbsp;001-34207 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>33-0728374</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or other jurisdiction</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(IRS Employer</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>of incorporation)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2929 Seventh Street, Suite 100 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Berkeley, CA 94710-2753 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of principal executive offices, including zip code) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(510)
848-5100 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Registrant&#146;s telephone number, including area code) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Former name or former address, if changed since last report)
</B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:10px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This Form 8-K/A is an amendment to the Current Report on Form 8-K filed by Dynavax
Technologies Corporation (the &#147;Company&#148;) on March&nbsp;21, 2013, regarding the departure of Stephen Tuck, Vice President, Global Technical Operations effective on March&nbsp;29, 2013. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;5.02</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
</B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(d) Compensatory Arrangements of Certain Officers </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Effective as of March&nbsp;29, 2013, the Company and Stephen Tuck, Ph.D., entered into agreements resulting from his previously reported
departure as Vice President, Global Technical Operations, including (i)&nbsp;a consulting agreement with the Company and Solutio Partners pursuant to which Dr.&nbsp;Tuck will provide advice and perform activities relating to his former areas of
responsibility for a period of six months in return for a fee of $350,000, payable upon satisfactory completion of the services, (ii)&nbsp;execution and delivery of a general release by Dr.&nbsp;Tuck in favor of the Company and related parties,
(iii)&nbsp;payment by the Company of COBRA continuation costs for an additional six months, (iv)&nbsp;extension of the exercise period for stock awards from 90 days to 12 months from the end of continuous service with the Company and
(v)&nbsp;payment by the Company of three months of executive outplacement service with a firm selected by the Company. These benefits are in addition to benefits to which Dr.&nbsp;Tuck is entitled pursuant to his Management Continuity and Severance
Agreement with the Company. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The agreements contain other customary terms and conditions. The foregoing description does not
purport to be complete and is qualified in its entirety by reference to the actual agreements attached as Exhibits 10.76 and 10.77 to the Current Report on Form 8-K/A, and incorporated herein by reference. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01 FINANCIAL STATEMENTS AND EXHIBITS. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(d) Exhibits. </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:28pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:39pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.76</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consulting Agreement dated as of March 29, 2013, by and between Solutio Partners and Dynavax Technologies Corporation.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.77</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Termination letter dated as of March 29, 2013, by and between Stephen Tuck and Dynavax Technologies Corporation.</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Signature(s) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>D<SMALL>YNAVAX</SMALL> T<SMALL>ECHNOLOGIES</SMALL> C<SMALL>ORPORATION</SMALL></B></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date April&nbsp;4, 2013</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Michael S. Ostrach</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael S. Ostrach</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vice
President</FONT></P></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.76
<SEQUENCE>2
<FILENAME>d516621dex1076.htm
<DESCRIPTION>EX-10.76
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.76</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 10.76 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>CONSULTING AGREEMENT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>T<SMALL>HIS</SMALL> C<SMALL>ONSULTING</SMALL>
A<SMALL>GREEMENT</SMALL></B><SMALL></SMALL> (&#147;Agreement&#148;) is entered into as of March&nbsp;29, 2013, by and between Solutio Partners (&#147;Consultant&#148;) and Dynavax Technologies Corporation (&#147;Dynavax&#148;). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dynavax desires that Consultant provide Dynavax with consulting services relating to areas formerly under his supervision in his position as Vice
President Global Technical Operations, and Consultant desires to provide such consulting services. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Now,
T<SMALL>HEREFORE</SMALL>,</B> in consideration of the foregoing and the mutual covenants and agreements set forth herein, and for other good and valuable consideration, the receipt of which is hereby acknowledged, the parties agree as follows:
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1.</B> <B>E<SMALL>NGAGEMENT</SMALL> <SMALL>OF</SMALL> S<SMALL>ERVICES</SMALL>.</B> Effective as of the date hereof,
Consultant will be retained by Dynavax to provide the services described on Exhibit A (&#147;Services&#148;). Consultant agrees to make available Stephen Tuck to provide the Services at such times and locations as reasonably required by Dynavax, for
the amount of time specified in Exhibit A or otherwise as necessary to perform the Services pursuant to this Agreement Consultant agrees to exercise the highest degree of professionalism in providing the Services and to perform the Services in a
timely manner consistent with industry standards. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2.</B> <B>F<SMALL>EES</SMALL> <SMALL>AND</SMALL>
T<SMALL>AXES</SMALL>.</B> Consultant shall be paid fees for the Services as described in Exhibit A. Consultant will be eligible for reimbursement for all reasonable travel expenses incurred when associated with the rendering of Services at locations
away from his home area, subject to the prior written approval of Dynavax. Consultant shall be solely responsible for all other expenses incurred in the performance of Services under this Agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dynavax shall reimburse Consultant within thirty (30)&nbsp;days of receipt of an invoice listing permitted expenses actually incurred, including receipts
for expenses in excess of $25. Dynavax will not be obliged to pay any invoice that is received more than six months after the date of incurrence. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Because Consultant Is an independent contractor, Dynavax will not withhold or make payments for state or federal income tax or Social Security; make unemployment insurance or disability insurance
contributions; or obtain workers&#146; compensation insurance on Consultant&#146;s behalf (except as required by law). All payments, including reimbursements for actual expenditures, shall be included in gross income as compensation for services
rendered and reported on an IRS Form 1099 Dynavax will provide to you. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consultant agrees to accept exclusive liability for complying with all
applicable state and federal laws governing self-employed individuals and other contributions based on the fees paid to Consultant, its agents, or employees under this Agreement. Consultant hereby indemnifies and defends Dynavax against any and all
such taxes or contributions. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>3.</B> <B>C<SMALL>ONSULTANT</SMALL> N<SMALL>OT</SMALL> A<SMALL>N</SMALL>
E<SMALL>MPLOYEE</SMALL>.</B> It is the express intention of both Consultant and Dynavax that Consultant is an independent contractor and not an employee, agent, joint venturer, or partner of Dynavax. It is further understood that Consultant is
retained and has contracted with Dynavax only for the purposes and to the extent set forth in this Agreement, and Consultant&#146;s relation to Dynavax shall, during the period of Service, be that of an independent contractor, and Contractor shall
be free to dispose of such portion of his entire time, energy, and skill as is not obligated to be devoted to Dynavax </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Page 1
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
in such manner he sees fit and to such persons, firms, or corporations as he deem advisable, so long as same does not create a conflict of interest between Dynavax and such other persons, firms,
or corporations. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The manner and means by which Consultant chooses to complete the Services are in Consultant&#146;s sole discretion and
control and at a location, place, and time which the Consultant deems appropriate. Consultant will, at Consultant&#146;s sole expense, provide equipment, tools, and other materials required to perform the Services, unless otherwise provided by
Dynavax in its discretion and Dynavax will make its facilities and equipment available to Consultant as necessary. Consultant agrees not to give any person or entity any reason to believe that Consultant is an employee, agent, joint venturer, or
partner of Dynavax. Consultant agrees not to bind Dynavax, unless expressly authorized by Dynavax in writing. Consultant will not receive any employee benefits such as paid holidays, vacations, sick leave, or other such paid time off and shall not
be entitled hereafter to participate in any plans, arrangements, or distributions by Dynavax relating to any pension, deferred compensation, bonus, stock option, health or other insurance, or other benefits extended to its employees. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4. P<SMALL>ROPRIETARY</SMALL> I<SMALL>NFORMATION</SMALL> <SMALL>AND</SMALL> I<SMALL>NVENTIONS</SMALL>.</B> Consultant agrees to
execute and comply with the Consultant Proprietary Information and Inventions Agreement and/or Non-Disclosure Agreement entered into between Dynavax and Consultant in connection herewith, and that a material breach of such agreement shall constitute
a material breach hereunder. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>5. T<SMALL>ERMINATION</SMALL>.</B> This Agreement shall be effective as of the date hereof
and shall continue until September&nbsp;30, 2013 (&#147;Term&#148;), unless terminated earlier as set forth in this paragraph. Dynavax may terminate the Agreement immediately upon notice and payment of the portion of the Consultant&#146;s fee
provided in Exhibit A equivalent to the percentage completion of the Term. Either party may terminate except for breach effective following notice and expiration of a 30 day period to remedy the asserted breach. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>6. A<SMALL>RBITRATION</SMALL>. </B>Any controversy, dispute or claim arising out of, in connection with, or in relation to the
interpretation or performance of this Agreement shall be resolved through binding and nonappealable arbitration administered by the Judicial Arbitration&nbsp;&amp; Mediation Services, Inc. (&#147;JAMS&#148;) in San Francisco County, California. Any
such arbitration shall be conducted before a single arbitrator to be appointed by the parties from JAMS&#146; roster. If the parties fail to agree to as to the identity of the single arbitrator, JAMS shall have the right to make such appointment.
The conduct of the arbitration hearing and discovery prior thereto shall be in accordance with the California Code of Civil Procedure, California Rules of Court, and California Rules of Evidence. There shall be limited discovery prior to the
arbitration hearing, subject to the discretion of the arbitrator, as follows: (a)&nbsp;exchange of witness lists and copies of documentary evidence and documents related to or arising out of the issues to be arbitrated, (b)&nbsp;depositions of all
party witnesses, and (c)&nbsp;such other depositions as may be allowed by the arbitrator upon a showing of good cause. The nonprevailing party shall pay the prevailing party&#146;s costs and expenses (including attorneys&#146; fees) of any such
arbitration. Consultant and Dynavax shall bear equally the fees and expenses of the arbitrator. The arbitrator shall decide the matter to be arbitrated pursuant hereto within 60 days after the appointment of the arbitrator. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>7. G<SMALL>ENERAL</SMALL>. </B>Consultant agrees not to engage in any employment or activity (whether as a consultant, advisor or
otherwise) in any business directly competitive with Dynavax during the term of this Agreement, without Dynavax&#146;s express written consent. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Page 2
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consultant agrees not to (i)&nbsp;call upon, solicit, divert or take away or attempt to solicit, divert or
take away any of the customers, business or patrons of Dynavax; or (ii)&nbsp;employ, solicit or attempt to solicit for employment any person who is then an employee of or consultant to Dynavax or who was an employee of or consultant to Dynavax for a
period of one (1)&nbsp;year following expiration of this Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">If any provision of this Agreement shall be declared Invalid, illegal or
un-enforceable, such provision shall be severed and all remaining provisions shall continue in full force and effect </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The term, Dynavax, as
used herein, shall include any subsidiary or affiliate of Dynavax Technologies Corporation. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">This Agreement shall be binding upon Consultant,
his heirs, executors, assigns and administrators and shall inure to the benefit of Dynavax, its successors and assigns and shall not, and nor is it intended to be, for the benefit of any other party. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">This Agreement shall replace as of the Effective Date any prior agreement between Consultant and Dynavax relative to services as a consultant, and this
Agreement contains the entire understanding of the parties. Further, it shall be amended only in writing agreed to by both parties and shall not be assignable by Consultant. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">This Agreement is entered into without relying upon any promise, warranty, or representation, written or oral, other than those expressly contained in this Agreement, and it supersedes any other such
promises, warranties, representations, or agreements. This Agreement may not be amended or modified except by a written instrument signed by both Consultant and a duly authorized officer of Dynavax. This Agreement shall be construed and interpreted
In accordance with the laws of the State of California, as such laws are applied to contracts executed and performed entirely within California. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL>,</B> the parties hereto have executed this Agreement as of the date first written above. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>A<SMALL>GREED</SMALL> T<SMALL>O</SMALL>:</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>A<SMALL>GREED</SMALL> T<SMALL>O</SMALL>:</B></FONT></TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Dynavax Technologies Corporation</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Solutio Partners</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ David Novack</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/&nbsp;&nbsp;&nbsp;&nbsp;Stephen
Tuck&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">David Novack</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stephen Tuck</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">02 April 2013</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">02 APRIL 2013</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dynavax Technologies</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="3" VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">2929 Seventh Street, Suite 100</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">[Personal ADDRESS]</FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Berkeley, CA 94710</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="3" VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Telephone: 510-665-7202</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="3" VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Email: dnovack@dynavax.com</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="3" VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Page 3
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT A </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>S<SMALL>ERVICES</SMALL>; F<SMALL>EE</SMALL> </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consultant will provide strategic advice,
knowledge, skills, information and experiences in the areas formerly under his supervision as Vice President Global Technical Operations. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">As
an advisor, he will review, provide feedback/comments and if needed write sections for the asthma CTA, FDA CRL, and 120 day questions from EMA. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Upon satisfactory completion of the Services on September&nbsp;30, 2013, subject to paragraph 5 of the Agreement, consultant will be paid a lump sum
payment of $350,000. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Page 4
</FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.77
<SEQUENCE>3
<FILENAME>d516621dex1077.htm
<DESCRIPTION>EX-10.77
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.77</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 10.77 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px">


<IMG SRC="g516621ex10_77logo.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:1px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">March&nbsp;29, 2013 </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Stephen Tuck </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">[Personal ADDRESS] </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Dear Stephen, </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Your employment with Dynavax Technologies Corporation is terminated effective
Friday, March&nbsp;29, 2013, and you will receive your final pay through March&nbsp;31, 2013 under our normal payroll cycle. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to
Section&nbsp;2(c) of the Management Continuity and Severance Agreement between you and Dynavax you will receive: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1) A
lump-sum cash severance payment equal to six (6)&nbsp;months of your current annual base salary (less appropriate withholding deductions). Your severance check is enclosed. ; </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(2) Six (6)&nbsp;months of COBRA Continuation paid by Dynavax, if you elect Cobra Continuation; </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(3) An additional six (6)&nbsp;months of vesting of your stock options to purchase Dynavax&#146;s Common Stock; and </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(4) Ninety (90)&nbsp;days from date of termination to exercise vested options as provided in the Dynavax Technologies 2011 Stock Incentive Plan. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><U>Group Insurance Benefits </U></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Your group health benefits (medical, dental, vision, and
EAP) will continue through March&nbsp;31, 2013. You may elect to continue your benefits as outlined under the COBRA provisions. A separate letter along with other COBRA enrollment forms will be sent to you by InfiniSource, our COBRA administrator.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">If you waived benefits coverage, you will not receive a COBRA package from InfiniSource. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Your group life insurance benefits (basic life, accidental death&nbsp;&amp; dismemberment, long-term care, business travel accident insurance) and short
and long term disability coverage will terminate on your last day of employment, March&nbsp;31, 2013. If you want to convert any of these insurance benefits, please refer to the &#147;Benefits Information for Departing Staff in your packet.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">If you and Dynavax engage in a consulting agreement, you will receive the following additional benefits upon signing a General Release:
</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">An additional 6 months of COBRA Continuation paid by Dynavax; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Continued vesting of your options, which will convert from ISO to Nonqualified status upon your transition to a consultant, and you will receive the
six months additional vesting as reflected above in #3 on September&nbsp;30, 2013; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Your exercise period will be extended from 90-days to 12 months from the end of your consulting agreement with the Company; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">3-months executive outplacement service with a firm selected by Dynavax. </FONT></P></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px">


<IMG SRC="g516621ex10_77logo.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stephen, if you have any questions regarding your separation benefits, please call me at 510-665-4604.
</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sincerely,</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Cecilia Vitug</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cecilia Vitug</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vice President, Human Resources</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g516621ex10_77logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g516621ex10_77logo.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`30#*`P$1``(1`0,1`?_$`*4``0`"`P$!`0$`````
M```````%!@,$!P(!"`H!`0`#`0$!`0`````````````"`P0!!08'$``!!`$$
M`0,"!`,'!`,````!`@,$!08`$1('$R$Q%"(505%A"'$R(_"!D<'Q,Q:AL4(8
M0R47$0`!!`$#`@,%!@0&`@,````!`!$"`P0A$@4Q$T$B!E%A<3(4@9&A0E(C
MT6*"%?"QP?&2,W(D-#4'_]H`#`,!``(1`Q$`/P#^_C1$T1-$31$T1-$31$T1
M-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$7P[_`(#?_0^WZDZ(
MJ-;99-KOD)32R?(T\EIOYSK<2.^%+<`6S+C-V2-BELE(4GDH>Z4ZTPQ3("6^
M(!6'(S32#M@205C3D&4OQ'Y$3&42BI;9KU-VK3#+[!"/*N4J7!9?96VLJ"4M
MM/<TI/JDD;PE7&),7=E77EWS@)BLL1_CP4M&OGD+B1[>*:^9(!6M"'?DQ$)W
M`3M)<CPEJ*BH`CQ[I/N-OJ/.S*0>.H5]66)'MSB8S]JLG+Z2HJV`!))V]`/<
M^P&PU1*-F[RG1:V8:G[5B2^@I*_("D$@K^GB-MMP5`<1MO\`QU(`@>;4J(`.
MHF"/L63R)^HE1V3[^G^/_CZ[:DWL7#.,/F+IY$G^51)]M@!OOMOL1MN/34)$
MQZ!T$HS^4LR^A8/XGU&X]/<>GJ`!N??0$GJ"%(!O%U[)`&^^W]OR.I`.AD(A
MST6(O-@\2H[_`)<23^.VP"=SOQ/^!_+1BH=ZM>TK2K;8G\?<;>WZ$`Z,5T60
MD6'5"Z@+X%7U?3N-B=N1(3N0-DE1'IO[ZXIHM:4`\CML"=]CL!Z^I.Q`]OQU
MT!RPZHL(D(4I:`LE3825IV')`5OQ*AQW'(#T_/7=C:^"XS:[ED+J![E7\>"M
MA[^YX^@]/?1BH=ZM>D.H<_D5R]COL=MB`H;$@;[I4#_`C458B7$+*@E044DI
M5M^"D[;I/Y$;^VB+T3M_H3_VT185.I2.2E%*>02"=DCDI8;2GZ@#R4L@`>Y)
MVU(1?HN-_,R%X#?<J`&^Y4.('$;DDE(``'XGTTV$]$V_S?Y+VEQ)V]2=R0#L
M=CL=B.0''WUP@Q+'JN]/%UDUQ$T1-$31$T14#L!XQZ=!27"53&CP:4EMQ02A
M]Q24+*3Q!W&_Z?B#K3CU1LFTB6^*QY4VAT'W*?QWR.TU<IYER.OP`*2I?DY%
M/H'4**G-D.;<AN=]CJ%P%=LH1Z`J[&D]$2PZ+2RRJ9L*F5O]+L7C-9<)6-G8
MVSI2%-[+"74)XG;\==HLEOV^"KR0#$EF*@L2M9MS73:NP4XU(90]#5*C.K;?
M(V<8==96XDK:>;<_D)!V.QU9:`)N&6/'G*RGL2)VDGX_>JS>T<BB=C1',CR=
MFMFKB--60R"R=LVWH-?XEE2U\HP7((+[G)#C3RPK^D/<]K$;0Y^<+/?C'#(%
M,I]LZERY?Q;[`NJ0(035MQ'9L^4E,-J-]P>D)^?('QTMF8N3&0R@RG2>96A"
M!S.X2/;6>>G1>O"BHUQD-SD>U8V:=(+;CDNU!$:2P&'+!UQ"0\4+#BR#]<I@
MH_IN[\T`G8^NN1F8EM"ZB<>!G$.6/O7+95;95&4C[),O[-%;6UUE/9L<FR&6
MR$RW;*(D_"?LTUTM+B:TDA2'%(5N>(WWUZ$31=#]X`>QM%CL[M&284$[=H=]
M5T^AO6+R.2@>-Y@)#[`5S#:CZ)*7``'4*`]"/8^A]=8K*S67\%LC,71VR^;J
MH"\Q^K<M83LJ7>@VUFEA;+60WD6&TOX*W.$>-$G,L1Q(^"@J2`$E0)`!4HF!
MZ.NBF!.KJYPXC%=#9CL%\LQD<$&1)DS'@A)/^Y(EN/R7BD'W6I1VUP$G13%<
M8:CJ%RG);AE&;TLE#<1URF5(AI4Y,80MIR<TA<\AI/E=2X8K30W4E.Z0H`@$
MG6RK'KG492^=G"QVY-L+!$-M)72["MCW<9I+TB>P$N)?9>K9\JO?!\3B$GRQ
M'6E+2II]6Z5;I)V5MR2DCS[9&N0;VK963;`B7BN7UF+ULO+)+EM(OK"93.Q9
M,%,C)+YRL0[%4VIF6*DVHJDOI0^G_P"#ZB25<CK=,D8L;8MN/58X4Q.0:R9;
M0'ZJQ7N(8S99!$?EU"I\ZP;"IS[TEYV,S"J4<&"(SSZF8[ID2D)"HZ$/*(W4
MK9)UD)5YJA[U:&H=9BM2\B"VN/#C_)D!#LF5*)?DOK?5N_*7*D;.RGN('+B@
M*`2```.+4JOB#KL.TN*^9$:BSY<G[E,+(2E,F5)0HNRBEM*&BI3;`!7MS6`.
M1]`!88AG"S56SG,QET"Z!(8;F1G8[W/Q2&7&G`VXME?!YM3:^+K2D.MJXK.R
MDD*2?4'?59ZK2>JXYD&&5E5)8?!MUTCDA`F,?\DRDNH=<Y(3Q+=MOXBP5A&W
MKY"`K<'TTPF=H`;HO/E23<93,NV_M5CG8I17C^/NM,V#@K([T6.ZS=V\*+"K
MG6V0MJ37Q+"/'LGGU1T(09#;JV_J5R'XP-LXD@-]RF<>N7RF3?$JU4V.5%%\
MS[9&7'$Z89TD*E2I/DD%`;Y@RGGBTGB/Y$<4#\M5RD9%SU6FJ`A':'9_'53V
MHJQ-$31$T1-$7/,_0R8E>7G.`^<H)0H;I=*V%)"%*"D*`]?8*&YUNP_G6#+^
M4JYU2TKKH93OL&$)V(XJ!2.)24[D@C;VUGR`U\Q_,5HQ?_CP^"@,UDAC';1"
MC(3\IA41"HB3Y@9"%(.R_P"5L;`@J.P`.NX\7L?P56=,5T@Q^<Z*$Z^JW&XB
M[%];JO.7/C)4VPVA#*WU.E*2P@!X<DC994HG\]694HBUJ_E91Q<80@)2??U5
MQNZF/<PGH<A;K:5A*D.L^/RL.H4%(=9+C;@"QMM['=)(U15882T5^3$65;)=
M%5L$LI=C7%$C^HS#4AEA[Q^/FE)V0KB%K4H$;[$GU_4:LR0!,$>(5.#.1K,#
MTB6"Z`H;D?P5_P!1J@>U;&_-XA5J(ZTO)K6*DH*V:2G<>2IM0>XR9UZ&3R4W
MXEMK\+AV"B0?<)W]9RF2`/`+-`;[Y3EU,659ML7>JY#EOCJ0R`%R'H3*WV_+
M(2XISFREHE"D.A:N302`2`1O[#1"\V0[-C;1J_C_`+:^Q4W52H/>IUF2S'HW
M7W:Z#Q7IG($7<W'VV2&9C=HMR?#<3NMIE%5/;\I9<;XNL_(4E/(*0MM:@?7<
M)U59`1!8N%HIM$]#\ZNMM9,U-3)L)!`1':1LGBM1<><<0Q'92A`6XI<B2XE"
M0`25*`U5'62G=*4*C*`>2X?DD#,[%8BN8E"D5T(R[7_D:+R(]9,V2FWD.-QZ
MTP4J>;>C2'&D@\5)&V_+8:V5V$2VCH0R\BWO']R0&FJZGA-N+C'H3VQ0XRDQ
MG6W!Q=1X#XT^5(X\7%M@'T`!W]/367*J&\=>JWX=AE`#350V3,JI+ZNR)N0W
M&B.I$6?Y5<&E%"'3]2N'%E*XYY$C=2BP$@;D'0V2-0J/R#[UVW]F[N1ZG16&
MBDKM'K*T=:2U&4^B'5/ID^5,RO9:0?E</J;:\\UQSCLI2RE()/J`(*RF7<=U
M\R%Z>^AF!6,PY,TGY:X\XR&8;C4=1"$OO,M/J;;=?VV^DD\?34Q`=3T4K;)`
M?LL3[US);V6P;ZFN<JA4U:]+EF"H4-A9V,>0B/'7(:\YF0(8C+=:YIX)2KD4
M[[^FVIZ,RQ43LA/=<`']B[LVI*T(4D[I4A*DG\TD`@_W@ZI/5>D""''0J'MB
MS(C.00MA<B:VX8K*R%%1:*=Y`"%!S@PI23R3[*(&^Y&\X^U0N(E#8/F7.L<M
MY5'?3:"QB3."Y#:&YCJ2&WEEI"H\F,5J_K,26E$#@5E*FG$J^M"P+35$U]P'
MS+#3;VSV;.H_W77DG??^)'\?UUF=UZ(;PZ+UHNIHB:(FB+$I92E2@GD0#LD>
MY(!(`_4D:[$.D_*"0N7VK.17L+X\^)41)*77G6FD64M'%:20VA1^!-;621]2
MR@A.YV0K6^NRFF0(A=(>+`?AKT7AWY/<E*!LHBQ/4R?X'3JL;,KLPPHC+==A
ML1]CS^1:KF[MT/--L[1F6_\`Z.B6VI<D[..'RAM`W2VHD#5=IQYVF9C<`?!A
M_CHM-&1;&F,8QKD`.N]G^QEOIJ;JZ?A/9&:IA,<(<<A09-A.0\LI`=3R?8K/
M&T'-]E*0Z2/7Z=]M5RR)5P->/3*7LD91!/V?A^*T?1RRP+;#M]P+C3WZ>Q7U
MDML-I9:0VVTV`EMM'TI0D#T2D)&P`UYEF5*,FN,(3]A+G[QHMQC&.A.JB;AZ
M[(C"E37#>0C[@[8*E;-0/&_S5$0PV4KF><M[!9"/'SW]>.^G%OQYO.R1D/Y.
MGAU=9KZKY_\`1LV^]_\`3[%1<>K\THVRTS!QJ0A;D)'RW;VX>?D0V7@W)?=8
M:Q>*Q\Y<5)*$A92E>R2I0]3JNOQK"#`6Z>X+'51R%$F@*C&1<ZE=34ZL<?1.
M^Q]]]M_3]?RW/]VLXE'],V^"W[,DPTV/]JYS&;[%2[/F.0,*382&4Q6'F;6]
M5%^/&D/O15R(BJE+JG"F4OEQ=]SZ:EOI_39]P6"$,^JPFP5")Z:E='2IU3:`
MM("^*2L)Y$!6PY`<MR1N?Q]=52M$0X$^OL6\0ME'S;/Q5/=QD1\@CWE<E`6I
M3@L([BE(0I#K:4B2R4-NJ\B/$!P`"5;[[@ZC&[<6VS_!9OIK:[>]&46]FJQ6
ME?ET^U?2U/QE./I;B.1($NFGS+`V,;=\NRY:;:-&3',@-\$I8+B0DD*"B-K8
M6`%Y1FWV*R0OD&_;;[5FFQ\N^U0F8<O&S<H,?[G+GUUB:MYK@ZF2B)$9M!,8
M<=="`E3CKJ4@DD*.PU9&ZK?K&S;]BKG5;.!C^VY^*K^,8]E.-*C1B_C"H3C[
M;TYN%`M()0'7I+DM$%ER7*:&P4@-J)2D_7NGU)U9=958'B)[_#IU7,>BZHB)
M,#%_>K3ED2;:4DV)7)AF>6TK@IGJ>1&5(0L'B\XPQ)>;;+>X*DMK.Q]OQUFB
M;26E66/CN"NR81)UD`5GCHF0ZQ,6(TVW)3$4TPZI+DIAN1X_H<6RTN&X\PAX
M[J2%-<D[#D"1J[;5^L*-4)5NSG^D_P`5`Q(N7)EPY$RZI'T(4$SA%QF5'<E1
M>3B_CL27LBEMQDJ6L;K#2S]/ZZZ\CT@?O"KIKR:RY#_TG^*Q9+3W=])AMLSJ
MB-51U1GS$ET+EC,3-86_SDQ+$6\5J,I<9WQA/@4I(Y'?96VD3)G,#_R"C?3D
M7!H@C^D_Q6W":RB+'GL.6M3,5XY2*AU=3+2J$\5+,+YZ3;NB8W%`0%I;\!6H
M$CB/01,9DN(2^\*RN&=&`@P8!AY9>'MU4?$@YDW9HL)EWC4M&P:<8;QBP:>3
M$/%3\>'*5DKR64O.IYDJ:</H!L=M2\S;=DOO"A'%Y#N]QX,3T,9:?BH2TQG.
M+2V>FO9/C3$!EYXU+;6&VBKBMB.NL._'=O#G26):S\=LK4(;*5%(V1MON[YA
M$U]J7_.(_!E1?AY<\@V$@>X1DW0#V^Y=`H6,B96^J[N(%G'5XD1&HM&]5KC.
M-\4O*>D.7-BF7Y%`D`-HX'\3J@%]6,?<X/XAEZ%$;(UM;\WP(_`JUZZK4T1-
M$31%HRTJ<8<:0\N.MU*VT26@V7(Y4VX/.V'FW6?(R#R3S2I!(&X(]-5][;&,
MH#<\V;IXZ_Y*4H[HM[5^8<,RO%\\NK*DP_\`<I?99:5RIQF5U3,Z<F2H;<.6
M[6RW'(D/K-J2VB%8(++FY7XW!Q602-_K^0PK>(PX9.?P>%*N1K&\W9NZ6X#=
M.8AE"$9%WVQB(ESM$0&'RM-N3E7Q%/*9E<9Y&36(B&$1#Z<ZB._$E,@=!ND9
M::RF=3L1\JQBUN7J*N_<)ECEM#SB5UK)JV(?6#L].<LT*\D=H78CO6+\D2XV
M/I5/Y!(9#+2EJ/`'?M^#.FB&9+@<$<?/!.7W/J<P'LQF8.(_7'4R!`B?/_+J
M'LK,K+31]?;.\:.:L9R?>1CQ#_`,H-[.<5B9#F.-J_<;FS][U]?8/CV8U"J_
MKQ4FBM>QGJBOPUB2Q&ZH;2^+N9<Q@E39<::6^.91ZI#^QY5^-A<A7PF)'CL^
MBVVJSN7$D5/NTGD3EIMD^^0(8[00RA//KQ[+\:W,D,C'VB0,(Z;XPE'Y-D=1
M./RQ\=7+E6//'Z?`XE1/SOO/.L=C9#D=-AU/(?G8?"%AD602E,5%8PU`P9"4
M2);C#H"N*0E#2U*(`WUYG&X^=RMAQN%X_'F*\:V^T"4QVX5@:ZS\SN?80V@D
M2`MN5.O"QX96??MJG(1W&+L3.,&+GPW"1/A$2)9BO=C1U^,W6)T]QV[VHJQS
MFVF4F,QI=S7N,SK*!07.52(@7"Q'P174T./S'P7EH!2R4@E7$&NGZG+-TJL>
MKM8Y`D09#0Q@TF,B_GGL+'P!U=A"RJF4:[3;/;9")##;I,/$$:^8D$'71EKN
MV^%M]8/]O2NU\Z:Z\9Q=[-7,E5?ICQT8PQ!?LU6H9%$Q(+"X;16D*;"E`CB#
MN-2KQ^0R.4CQ./C5RS97QIV[F\W20?<WE.@U:75PJC'%IP+\^=D_I*:I3W;C
MJW0,SZZ_!NA=;$U_$ZCK*5V?([#['F8,WBL?,E7D*^L9\TXXJK8GBR8C1:[Y
MCB/MX#[@#?))*R1OOJZG#Y"SEI<)+'A'DXWSJ$3(,3'^8R$027`#EST)=<P*
M*\K'KSZ[I_0641MWDG1P20S.6]NGP4KBE#C&<,V*Z#/^QI\7'+Z70RK!K+[0
M1YMC7M1'9K<>8CQM642.[*+"W&MVQ(:=;W"VU`9^0AE\59"O,HA"ZVL3`<N(
MR=G&YXG1V(!9BS$*['AA\UC]['G9V(6&(D_S$=?#^*I?<68];]$PJJRSJY[P
MD0;YZ9"8FXNOL[+(L`U30=?>NG<5:G(QYN49"&V7)`:3*?*6FBI>R=>APN'R
M7.97T7%TTSR1$R8[`X#/K9(`_!R6<LSJ'(58/&XOU&1*W:X'S'J?@"H'+,^Z
MEPK`,#["N?\`V#DU_95G`H<6I*Z5WA9YK)MKC'[O(XT2=A4*?_R&K>9IZ&4\
M^),=HQDM;N<?8;^&X;U%S?(9&!@T8/?QJY62WVXM4>W`Q$CW+YU5.\@!$3)D
M2T7.BQ<G;Q7&\97R>3.Z.-:S,;)%R#M&V$92U8Z[=/%>KW.^JZ3K+&>T[YG]
MP%3"RN5`JZ'#E77<['9%C>W4R6U`QY.!Q[I%\B[6B,X[XG&4>..VIUQ2&FUK
M&:O$YS)YF[@L&G!LRJ)3$YF>-V8BLUB4C?&4ZMC3<2$R"0`/F!6>R_AJ./JS
MLFR^/>/ECMN<^/64(L6!Z@=/>%-UU_U?.ZUQ;L2LN>W)6-9?<8Y0TX<SSLQN
M_:N<IRB%AT>!;PK._:G5#U7D,WX\Y,DI^&IESD/H]5O'\Y5S.1P]U&'WZ*I3
MGLE7(B,([Y$;0($;/,#"R1/1G<#54.%LQ*<SOW"JZ8B/FT)]O^`M*RR3J>EP
MWN#L"SN>W1C_`$I,R"#F;[G8W9"'>>*XU59#:+IHR<IB"?&3`N$[.;MI6^A1
M"N`2LX:\#F\K-P>(.-7'.Y+'$ZA$UES.SM1BY\KF;@&>T::QVE3QH<3?CRS(
M76]FNS:7,N@.I^[7H5N8;'ZCS>HG7U3D_9J*6!CV.YM*LK#N?MB.S&ILCI)%
MO"?D<L[48;;$"(XIYM80AM2?Q(.S(P/4O#YU&%D8U.[(E97$RHPK!*==FPPV
M_32/S$`EP[L"0HTPX/D<:W,JMM%-).[60T`=]"#T'0:CVA0'3F2],]W?>G\.
ME]XPW:.%33DLY=GO[@,47=8YE"9JL:RVA:NLPC,W..7BJJ2F/-C\T%;*QN/Q
M]CEK?4GIR!&=A<((]V^K_P"KXR9&1BD"^D_^M(@UF47/RR!<.%FXRGA^6UQI
MW].X/_8RP]'A;_WCK^GK[U=^LIW5G:W7M=V;B]KV<QBMNJ]2TN^[)[7J[".,
M;O+7'[14R')S)UR&AJ?3/D*Y;%`2KV/I3SX]0^G.;M]/<C#`'+TVPKE".!QD
MAOLB)0&X83%Q(:@%2XN/`\OP\.<PYY!P;*9VQ)R,H$UP)$I?]^A&TZ>/M5,Z
MD[#Z>[AN+"@QMSNJJE)QB#F%2[E69=QT43+,+L+694P\KQ&=,RXHLJER9``4
MM):?;2\T5H"'D*7?S^-ZA].XU>9FCC;*IS[9%6%Q=DH7!MU-D1AC;(/U<Q(U
M=EWC:.*Y&9I`OADQK%IC]3EG]F7RV`]T.X(.UG!T?Q6WAO8'46==A2>OJ&3W
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MC;#0.[Z.RP8EE>%Y=B^795<8C^X;KC'<,KU74NP[`S//\?%G5)K9EE+M*)VG
M[+MW9L*%#A$O%194V%I/'=6JLV>51R$.*HRL#(Y"4S&4*\*F`K(EM`)G@4U'
M=U':E,?J(DX6W$QL2RJ^55.7"C',AYLNTO*+[P\LN,@(R!#RB'_*X71>CLJI
M,LK;.QI\4[;Q5"9<`?$[3MKRW=L8DV%%L*ZYH9T_+\VJ)=9*B2D\C%EAQIW=
M#[:'4E*?.]1X-_'Y<1;?C9,BT3*F':C$AP8F!IH.Z)T)%>V7Y9R8MZG!9E63
M@QLJKLA`R.D[#9+KUW&RUQ[M^GL"_08._P#;^_\`SUX$9QD9"/Y2Q^+`_P"J
M]\AE]U)<31$T1:[S:EMJ2"!OOZ[\=OI4/YO=.Y/N/75?;:=<J](QDY]ZGN#K
M\7]-_MOSC"L@Z\G93=X@:GJVL[1@8^UC3-TY;7CO9=Y"LI#E_-M68S3,&MB5
MZ!\9A+J7I)2YY$I:0@_H?->J>+S\#(IQ*LD9.3.B4NY*)A#LQD^T1#G<9:.V
MV(;7P^`XOTEF87+1S[[XRIAG9]XB`7,<N9E&)?1X`L?:VBZTQTC7QN^;#N-A
MJH:^X8-"Q]]EMF0F>YD3%F]\F]=2%_;7)$K&T1:\R/%\P,1@UY/"2@_-7<[G
MY'I"/IBZ<C.&:+HS#,*PQ[/ZNV9/(Q?:\B6=E]&.&HAG#-KTEXO]RXKD_P"S
MV9>]C9;V9$RZ#57V1]R]9]@J^-7S$L66%X+58!"EX)D[(E>"V#EMA0M8,@H'
MPYWC4E._D4K[?"__`$2.+P>#P-E,[,/"P\NJ+D>6S*LOF;(::"(OE6WZ`!^4
M+Y?GO15W*YG(YV-=&J_-S,.V+@G;#'JHKLK+=>X:B8MH'#^*OG[AOV[WW?,>
M%3G.O^)4-7C^2""W6TM-863F974=%=`NI,C(*F[C18-+5JD(:^(U'GI7+6IN
M2WL-_"]'>J,;TI.>1&F=F3?;4+2)`"6/`F4JO;^X2!)]&'1>_P"HN`K]181X
MO(F8\?.R9DWSB-D)43VGH#V+K]I\+>U/\JG^V.F<I[-ZPJ<98S&OQGL2HD4-
MO79]%I!8MU61Q6A7W]G65<YY2VD6U'/L(K:5.\VD2]BM02>6+@.<Q>%]279]
ME,KN`MJM@:-P$FE*4ZGDQCY)"LG0OM+=0U^7QN3E<0,0SA'D&$MX!VBP'>6'
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M3F0MG[@X4/2F4MJ=27@XZ[D]3\O/U)S$^;N!CFY`@;G(VFR,=FZ$0`(0,0/+
MJQ?5F4N`XF/!<;_;:Y;JA9*0_JU8^U2O<77'_P"K]?7F"IMOL*KEZE=%J(7W
M`QOM-[67*Q\0281=^0BO+7^ZGB5\CN!Q-GISF?[!S%7*F!L%6_RB6U]T)1^9
MI,SOT*OY3CJN4PSB6EHF0/W*C=W=&2>WJK"84;(*NCE81FS>;0U6U#/R&HL9
M3>'Y;AZ8-E6UF28C8.1A&RUQ_=J<R2XP@$%)4-<](<[E>F<W(S;C9=._CYXW
MDF(&,I7"SN>:NP2#1$3%@3UW!ECYK@,7F>(JXFWRU5$2?4N8@MT(T<ZZJ/LN
MAKR?A_45<QEV/5&:].W<._QV\J\+FHPUV9'Q')L!>A/8-.S"?8IJGL1RV4PV
MG[VJ3'D);=#Z@DMJV8?J..+G<E.='<X[DXS%L3,"P;KJ;XF-@@`"+*0_D8Q\
MK!],EOIP7\?CX]DH')Q2\);3MU!CJ-Q_*3[==5L9)T-8YKU72]<9GFPO93&8
MXAEV39`SC\?'F\@./=A5^>651#J,<G5@HH-F(:H##B9+\MAA0<?>EOA;CD.+
M]1RX?U'=SF!1",)XUE4!*1G.!G4:Q(F0,9;'W,8L3H0VBW_VH6<;5QV1VS&,
MP9$!G#DG;["55O\`U:3'ZA[TZEJ,J@U,/M^_R>YJ[(X_,M$XBUDV/T%2MB9#
ML,D7(RF3$G5#LHO+E0_.'PV4H+?D7IK]6Y,>7XGF90?*XO'A".H:4X72NC(>
M70/(!BYT=]6&;%]/8V+@6X$">W9,D_`^'Q96'%OVUT>.U_>>.O6[T[$.ZWY7
M/&T1RQ'P^MM\730Y%2T*WI$QANJM+63/M6F`RVW%DV#J$A:`#ID^L.0R+.,R
M2!]9QMLK!,E^Y,VQLC*08%P(QC(DDR9]"HX/IK$PL/)P@2:L@E_<)!B/Q+>Q
M9^H^AK/KNTGWV2YNC.[UW",)ZVKK!.-QL61&P[`9623J9N="@3YT2;>RI>4R
M%RY3*8C"^#8;C-`*Y9_4OJ.7/U=JFKL0^HR<G61F^3EB$;INP:)%<6CJ1J3(
MDIQ'IZKB"]<A*0K[`T9L4=(?^8_5T6/IOH*QZLP:9UG89;797@R&\C8HJT8P
MY264"-DV09%=V#%C;"^M46OT7W@04QX_$-<B%%9`V^K/5Q]3^I9>K.SV>8G=
M3:3NW1[E$(0K(&V+`;(KSO37I(^GO3]?IR-HGA4X]E$-"#V[3(R=R7/F++7Z
MM_;Q.P+*(.49!GCF92,<ZVB=28;&&.Q<>;J,+BV-=9*%NJ)/F)R"]DN4L)"I
M`1$8;;8(:CMEUTKS<]ZE'+U3HQJ!BUVY)R)[9&1-\@=T@X#1)E([?!^J]#BN
M!GQ]ARK+(SRS0*'`8=F+"(;]0`&OM4'U;^UN1U9FU?>U78MO)P^AD9\YCV$.
M1YS;3,;L.]FY/:Q;V>B\%;D7VW()SK]<^Y6MRX;3SC!>=0H$7<MZHQ^5XR6)
M+"JAG6=HV7`EY3KBT[-OY97'SS`.W=T`5'%>F(<5R8RZI@XD(&,(,7`/1R[%
M@K/`_;M"AX_W]CSF1OOL=]9#G=[92Q6Q&7Z%.<XG48I(B1FDE3-@8$:J2M+C
MO%3FX2H;)]=&=ZYS\WDO3_)2@=_I[%Q*:AO+3&-DWW[I:>7=WMK!V(=4S]'X
MMO'<QQULGKY2>07_`$1R:Z:[1[W%,&^"P=6_MZ<ZUPW+L*CW^,-5^3H<\,C$
M>MJ/$GH4J54"KG6EC$DSLDJ,CM7E-MN!<J-X=FPVXRXCD%8.;]15<MR5?*UT
MV5949RE)[3,2)EN!`VQV$>)#D]7"W8O`SJHR:;[*YG),I']L'SS<S)<EP9$D
M#P&BV>@_VYTO0S66)I;&$Z,NN8MQ+JZ#'*["L0K784006UTV'TRW*JLG3F$)
M7-?:*1)?W4EMM.S:<_J7GY^HKJK95FLUQ`)E,V3DW4F9`)?WN?>5?PG"QX;#
MCAPE$P$B?+':-2_35?H\#;?\R=S_`(`?Y:^;C7&!D8_FDY^+`?Z+WB77W4UQ
M-$31$T1?`E(]@!Z[^@`]?S_CHB^Z(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)
MHB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(
MFB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)H
3B:(FB)HB:(FB)HB:(FB)HB__V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
